Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian   Blake Lesley   Kagan Ethel   Resnick Malca  

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 8, Iss. 2, 2011-03 ,pp. : 175-186

Bentham Science Publishers

Access to resources Recommend Favorite

Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies

By  

Current Alzheimer Research, Vol. 12, Iss. 3, 2015-03 ,pp. : 242-254

Bentham Science Publishers

Access to resources Recommend Favorite

A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results

By Viala Annie   Cornic Francoise   Benamor Cyrine   Baldacci Chantal   Cheref Smail   Gauillard Jacques   Martin Pascal   Caroli Francois   Vacheron Marie Noëlle  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 2, 2009-06 ,pp. : 138-146

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Potential of Preventive Treatment of Alzheimer's Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome

By Gavrilova S.  

Neuroscience and Behavioral Physiology, Vol. 41, Iss. 4, 2011-05 ,pp. : 391-398

Springer Publishing Company

Access to resources Recommend Favorite